Dr. Vose elected to clinical oncology society board

Julie Vose, M.D., has been elected to the board of directors of the American Society of Clinical Oncology (ASCO).

Dr. Vose, the Neumann M. and Mildred E. Harris Professorial Chair and chief of section of hematology/oncology, begins her four-year term in June.

Julie Vose, M.D.

ASCO — the world’s leading professional organization — represents physicians who treat people with cancer. It also sets the standard for patient care worldwide and leads the way in clinical research to improve the prevention, diagnosis and treatment of cancer.

“This is a very exciting opportunity for UNMC to be involved in setting national health care standards and policies in hematology and oncology,” said Dr. Vose, one of the country’s leading experts on lymphoma. “It will give us a voice and a seat at the table with other oncology leaders from around the country and world to improve oncology clinical care, research, and education.”

Dr. Vose’s election to the board is a testimony to her expertise and international recognition in clinical oncology, said Lynell Klassen, M.D., professor and chairman of the UNMC Department of Internal Medicine.

“It reflects what she’s done,” he said. “To be elected at this level by a group of peers is truly noteworthy.”

Dr. Vose is principal investigator or co-investigator of two National Cancer Institute grants and other clinical research grants totaling more than $6 million. She has authored or co-authored 240 manuscripts, 40 book chapters and 230 abstracts and has given more than 400 lectures and presentations internationally.